Immunic, Inc. financial data

Symbol
IMUX on Nasdaq
Location
1200 Avenue Of The Americas, Suite 200, New York, United States
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 150 % -55.1%
Debt-to-equity 184 % +333%
Return On Equity -716 % -302%
Return On Assets -252 % -101%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 120M shares +33.5%
Common Stock, Shares, Outstanding 98.7M shares +9.52%
Entity Public Float 100M USD -8.68%
Common Stock, Value, Issued 9K USD +12.5%
Weighted Average Number of Shares Outstanding, Basic 194M shares +91.5%
Weighted Average Number of Shares Outstanding, Diluted 194M shares +91.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 84.5M USD +8.77%
General and Administrative Expense 21M USD +16.1%
Operating Income (Loss) -106M USD -10.2%
Nonoperating Income (Expense) 2.49M USD -69.5%
Net Income (Loss) Attributable to Parent -103M USD -6.34%
Earnings Per Share, Basic 0 USD/shares +32.5%
Earnings Per Share, Diluted 0 USD/shares +32.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 35.1M USD -40.5%
Other Assets, Current 818K USD +8.06%
Assets, Current 39.3M USD -37.9%
Property, Plant and Equipment, Net 640K USD +3.56%
Operating Lease, Right-of-Use Asset 791K USD -9.91%
Other Assets, Noncurrent 0 USD -100%
Assets 40.7M USD -37.1%
Accounts Payable, Current 7.92M USD +31%
Accrued Liabilities, Current 19.5M USD +19.8%
Liabilities, Current 30.1M USD +28.8%
Operating Lease, Liability, Noncurrent 126K USD -32.3%
Liabilities 30.2M USD +28.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax 2.58M USD -33.6%
Retained Earnings (Accumulated Deficit) -589M USD -21.2%
Stockholders' Equity Attributable to Parent 10.5M USD -74.5%
Liabilities and Equity 40.7M USD -37.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -21.8M USD +9.15%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities -47K USD -51.6%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 98.7M shares +9.52%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -21.4M USD -142%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 35.1M USD -40.5%
Deferred Tax Assets, Valuation Allowance 117M USD +18.2%
Deferred Tax Assets, Gross 117M USD +18.2%
Operating Lease, Liability 792K USD -11.9%
Depreciation 42K USD +23.5%
Payments to Acquire Property, Plant, and Equipment 47K USD +51.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -104M USD -7.66%
Lessee, Operating Lease, Liability, to be Paid 832K USD -12.1%
Operating Lease, Liability, Current 666K USD -6.59%
Lessee, Operating Lease, Liability, to be Paid, Year Two 87K USD +11.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 449K USD +3.7%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 40K USD -16.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 84K USD +2.44%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD -100%
Additional Paid in Capital 597M USD +14.1%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 43K USD +65.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%